SIK2 is a multifunctional kinase of the AMPK family which plays a role in CREB1-mediated gene transcription and was recently reported to have therapeutic potential in ovarian cancer.
Introduction
Prostate cancer is the most common cancer diagnosed in men and the second most common cause of cancer death after lung cancer, with around 40,000 men diagnosed and 10,000 deaths annually in the UK.
[1] If diagnosed early, it is generally successfully treated using radical prostatectomy. However, 10 to 15 % of the patients are diagnosed after their cancer has spread and present with advanced or inoperable cancer. [2] Since androgens have been shown to play an important role in the progression of prostate cancer, removing or blocking the action of androgens using hormonal therapy, also referred to androgen deprivation, is the treatment of choice for patients at this stage. It usually results in a favorable clinical response with the initial regression of at least 80 % of hormone-sensitive prostate cancers. However, 10 to 20 % of men eventually fail this therapy since tumour cells acquire the capability to grow in the absence of androgens, and the disease eventually recurs with fatal hormone refractory prostate cancer (HRPC). [3] Consequently, new approaches are needed for the treatment of prostate cancer so biomarkers for diagnosis and novel targets for therapeutic intervention are urgently required.
Salt-inducible kinase 2 (SIK2) is a serine/threonine kinase that belongs to the calcium calmodulin kinases (CaM) superfamily and the AMP-activated protein kinases (AMPK) subfamily. The members of this family act as sensors of cellular energy changes, and are known to regulate physiological processes that consume or generate ATP in order to maintain energy homeostasis in the cells. [4] Several studies report that SIK2 is activated in refeeding from starvation and modulates homeostasis in order to help the cells to adapt to metabolic stresses via the regulation of CREB1-mediated gene transcription. [5] [6] [7] [8] [9] [10] [11] cAMP response elementbinding protein (CREB1) is a transcription factor which binds to DNA sequences called cAMP response elements (CRE), thereby stimulating gene expression once phosphorylated at Ser133. [12] The activity of CREB1 is enhanced by the transducers of regulated CREB1 activity (TORC) via a phosphorylation-independent interaction with the bZIP DNA binding/dimerization domain of CREB1. [13] The TORC family is composed of TORC1, TORC2 and TORC3 and all three TORC isoforms contain the putative SIK2 phosphorylation site and are downstream targets of SIK2 in the regulation of CREB1-mediated gene expression. [14] Few studies have provided evidence of a role for SIK2 in cancer. SIK2 gene is located in the commonly deleted region of breast cancer at 11q23.1. [15] [16] [17] In contrast, this region is amplified in diffuse large B cell lymphoma (DLBCL) which results in increased SIK2 expression at the RNA and protein levels in tumours, where SIK2 was found to regulate survival and glucose metabolism, suggesting its role in DLBCL progression. [18] In addition, SIK2 has recently been identified as a centrosome kinase controlling the G2/M phase transition in ovarian cancer. It localises with the centrosomes where it phosphorylates the centrosome linker c-Nap1 at Ser2392, resulting in its translocation from the centrosomes to the cytoplasm at the onset of mitosis to facilitate loss of centriole cohesion as an initial step in centrosome separation. [19] In the present study, we found high levels of auto-antibodies against SIK2 in plasma of patients with prostate cancer. We show for the first time that SIK2 is present in prostate cancer cells, and that its depletion inhibits growth and induces cell cycle arrest and apoptosis.
Using immuno-precipitation, reporter assays and cellular fractionation methods, we found that SIK2 interacts with the CREB1 regulator TORC1 and negatively regulates CREB1 activity by interfering with TORC1 nuclear translocation. Using a whole genome profiling approach, we then identified the genes and networks regulated by SIK2.
Material and Methods

Protein array profiling of plasma samples
The study was performed on a patient cohort comprising men who have received prostatectomy and for which there was at least 5 years follow-up and assembled as part of the ProtecT Study (Prostate testing for cancer and Treatment). The disease of men with likely indolent cancer is characterised as follows: PSA<10 ng/ml; pStage <=T2; prostate cancer volume <=0.5 ml, and no PSA recurrence >5 years follow-up, while the disease is classified as likely aggressive disease if there has been clinical/PSA recurrence, or if in the post-surgery pathology pGleason >6, pStage >T2 or prostate cancer volume >0.5 ml [20] . Plasma samples were analysed using ProtoPlexTM immune response assays as previously described [21] . All experimental work was performed at the service laboratory of the array supplier (Invitogen, Carlsbad, CA, USA).
Cell culture and reagents
LNCaP cells were obtained from ATCC. C4-2 cells and C4-2b were obtained from MD Anderson Cancer Center, Houston, TX. LNCaP-Bic cells were a kind gift from Dr Zoran Culig (General Hospital Feldkirch). DuCaP cells were a kind gift from Philips Research (Eindhoven, The Netherlands). SKOv3 cells were a kind gift from Dr. James Brenton (University of Cambridge). LNCaP, C4-2, C4-2b and DuCaP cells were maintained at 37°C in RPMI 1640 (Invitrogen) containing L-Glutamine and supplemented with 10 % fetal bovine serum (Fbs) (Gibco) in a humidified atmosphere supplied with 5 % CO 2 . LNCaP-Bic cells were cultured under the same conditions but medium was supplemented with 1 µM Bicalutamide (Enzo Life Science). Cells were routinely sub-cultured 1:4 using 0.25 % Trypsin-EDTA (Invitrogen) when 80-90 % confluency was reached.
Forskolin was obtained from Sigma-Aldrich. A SIK2 inhibitor, ARN3236, was obtained from Arrien Pharmaceuticals with reported low nanomolar IC50 for SIK2 both in activity assays and cell-line experiments. [22] SIK2 siRNA sequences were obtained from Dharmacon. [19] The non-targeting siRNA was obtained from Dharmacon. The pCMV6-Entry-myc/flag construct was obtained from Origene. The pCMV6-Entry-WT-SIK2 -myc/flag and pCMV6-Entry-SIK2-EOS-KI-myc/flag were generated as previously described. [19] Cell transfection
AMAXA nucleofection
For AMAXA nucleofection, 2x10 6 cells were mixed with 100 µL Nucleofector solution R (Lonza) and 10 µg of DNA construct or 1 µM of siRNA duplexes. An electrical current was then applied to the cells (Nucleofector programme T-09) to deliver the DNA or siRNAs into the nucleus. Cells were then transferred into culture dishes containing RPMI 1640 supplemented with 10 % Fbs.
Lipofectamine transfection
For each reaction, siRNA duplexes at 40 nM were mixed with 6 µl of Lipofectamine TM RNAi
Max (Invitrogen) and 500 µl of Optimem (Gibco). Mixtures were incubated for 20 min at room temperature (RT) and then dispensed in a 6-well plate before addition of 200,000 cells in 2 ml of RPMI 1640 supplemented with 10 % Fbs.
DNA preparation
All the DNA constructs used in this study were expanded using the XL10-Gold ultracompetent Escherichia coli cells (Agilent Technologies) and were purified using HiSpeed Plasmid Midi Kit (Qiagen) according to manufacturer's recommendations.
Cell counting and Cell viability
fluorescence at 520 nm. To measure colony formation of cells after transient knock-down, cells were transfected with siRNA, trypsinised 24 h later and 10,000 cells were reseeded in soft agar as described above.
Cell cycle analysis
For DNA content analysis, cells were seeded in triplicate at a density of 300,000 cells per well in a 6-well plate and were grown for 48 h or 72 h. At each time point, cells were trypsinized using 0.25 % Trypsin-EDTA (Invitrogen), were washed in 1X PBS and were fixed with 1 % paraformaldehyde (Electron Microscopy Science) for 1 h at 4°C. Cells were then washed in cold 1X PBS (Gibco), resuspended in 80 % ice cold methanol and stored at -20°C until staining. Methanol-fixed cells were treated with 3 μM DAPI (Sigma-Aldrich) overnight at 4°C. Fluorescence activated cell sorting (FACS) analysis was carried out using a BD LSRII instrument (Becton&Dickinson, San Jose, CA) and data acquisition was performed using BD FACSDiva software (v.5.0.3.). The fluorescence emitted by DAPI was collected using a UV-450/50 bandpass filter. Data were analysed after doublet discrimination [23] using the FlowJo software (Tree Star, v.8.8.4.) and applying the curve-fitting algorithm contained in the software.
Annexin V Apoptosis assay
Cells were seeded in triplicate at a density of 300,000 cells per well in a 6-well plate. 
Immunofluoresence
Cells were seeded at a density of 50,000 cells per well in a 24-well plate with coverslips.
After at least 48 h to allow adherence, cells were washed in 1X PBS and were fixed with 4 % paraformaldehyde (Sigma-Aldrich) for 3 min. Cells were then washed in cold 1X PBS (Gibco), treated with 80 % ice cold ethanol and stored at -20°C until staining. For staining, cells were washed in 1X TBS-0.2 % Triton-0.04 % SDS, blocked for 30 min with 1X TBS supplemented with 1.5 % bovine serum albumin (BSA) (Sigma-Aldrich) and incubated for 1 h with a SIK2 (BioLegend) or γ-Tubulin (Sigma-Aldrich) primary antibody followed by an appropriate AlexaFluor488® or AlexaFluor594® conjugated secondary antibody (Invitrogen). Cover slips were then mounted onto slides with Vectashield solution containing DAPI (Vectashield). Images were taken using a Leica Tandem confocal microscope.
Time lapse imaging
Cells were seeded at a density of 40,000 cells per well in a 15 µ-Slide 8 well plate (Ibidi).
After 36 h, the plate was placed in an incubator in a humidified atmosphere supplied with 5 % CO 2 connected to a Nikon Eclipse TE 2000 microscope (Nikon Instruments Europe).
Images were obtained using 40X lens and were collected every 5 min for 48 h from 4 different positions per well using NIS-Elements AR 3.2 software (NIS Elements). The time from the start of pro-metaphase, as evidence by the cells detaching and rounding-up, to the end of cytokinesis, as evidence by the generation of two daughter cells, was scored for individual cells. The exact start time of pro-metaphase for each cell was recorded to avoid duplication of measurement.
Preparation of total cell extracts
Cells were washed, scraped in ice cold 1X PBS, pelleted and resuspended in lysis buffer containing 20 mM Hepes (pH 7.5), 150 mM Sodium Chloride, 1 % NP-40, 0.25 % Sodium Deoxycholate, 10 % Glycerol, 40 mM Sodium Fluoride, 12 mM β-glycerophosphate, 1 mM sodium orthovanadate, 0.5 mM EDTA, 2.5 mM EGTA, a protease inhibitor cocktail (Calbiochem) and a phosphatase inhibitor mix (Sigma-Aldrich). The extracts were cleared by centrifugation (8,000 g for 10 min at 4°C) and supernatants were collected. Protein quantification was performed using the Quant-iT Protein Assay according to manufacturer's recommendations (Invitrogen). Total cell lysates were boiled at 70°C in 5X SDS sample buffer for 10 min and immunoblot analyses were performed as described below.
For treatment of the extracts with a phosphatase, the same procedure was followed but the extracts were prepared in NEBuffer 3 (New England Biolabs) and were sonicated for 90 sec before being treated with Alkaline Phosphatase Calf Intestinal (New England Biolabs) at 1 unit per µg of protein for 2 hours at 37°C.
Preparation of cellular and nuclear extracts
Cells were washed, scraped in ice cold 1X PBS, pelleted and resuspended for exactly 10 min in lysis buffer containing 10 mM Hepes (pH 7.9), 10 mM Potassium Chloride, 1.5 mM Magnesium Chloride, 0.34 M Sucrose, 10 % Glycerol, 1 mM Dithiothreitol, 0.1 % Triton, a protease inhibitor cocktail (Calbiochem) and a phosphatase inhibitor mix (Sigma-Aldrich).
The extracts were cleared by centrifugation (1,300 g for 4 min at 4°C) and the cytoplasmic fractions were collected and cleared by centrifugation (20,000 g for 15 min at 4°C). The nuclei were washed twice in lysis buffer containing 10 mM Hepes (pH 7.9), 10 mM Potassium Chloride, 1.5 mM Magnesium Chloride, 0.34 M Sucrose, 10 % Glycerol, 0.1 % Triton, a protease inhibitor cocktail (Calbiochem) and a phosphatase inhibitor mix (Sigma-Aldrich). They were then resuspended in lysis buffer containing 3 mM EDTA, 0.2 mM EGTA, 1 mM Dithiothreitol, 0.1 % Triton, a protease inhibitor cocktail (Calbiochem) and a phosphatase inhibitor mix (Sigma-Aldrich), sonicated for 90 sec and cleared by centrifugation (20,000 g for 15 min at 4°C) to obtain the nuclear fractions. Protein quantification was performed using the Quant-iT Protein Assay according to manufacturer's recommendations (Invitrogen). Cellular and nuclear extracts were boiled at 70°C in 5X SDS sample buffer for 10 min and immunoblot analyses were performed as described below. 
Immuno-precipitation
Western blotting
Immunoblot analyses were performed using a range between 20 μg and 100 μg of lysates depending on the abundance of the protein of interest. The material was electrophoretically resolved on denaturing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) gels ranging from 6 % to 16 % acrylamide and was transferred to nitrocellulose
Immobilon-P membranes (Invitrogen) using the iBlot™ Dry Blotting System (Invitrogen). Blotting Detection System (GE Healthcare).
RNA extraction and cDNA synthesis
Cells were washed, scraped in ice cold 1X PBS, pelleted and resuspended in 1 ml Trizol reagent (Sigma-Aldrich). Samples were incubated for 5 min at RT, mixed with 200 μl of chloroform and cleared by centrifugation (12,000 g for 15 min at 4°C). The aqueous upper phase was saved and incubated with 500 μl isopropanol for 10 min at RT. Samples were centrifuged (12,000 g for 15 min at 4°C), supernatants were removed and pellets were washed with 1 ml 75 % ethanol. Ethanol was discarded after centrifugation and pellets were resuspended in RNase free H 2 O. RNA quantification was assessed using NanoDrop™ 1000
(Thermo Scientific). 1 μg of total RNA was reverse transcribed using the High Capacity RNA-to-cDNA MasterMix (Applied Biosystems) according to manufacturer's recommendations.
Quantitative Real-Time PCR (qRT-PCR)
Reactions were performed in triplicate using 5 μl of FAST SYBR GreenPCRMaster Mix (Applied Biosystems), 2 pmol of primers ( Data were normalized to housekeeping genes β-Actin and SDH, and the ratio between the sample of interest and the reference sample was calculated.
Illumina HumanHT-12 v4 Expression BeadChip
Cells were washed, scraped in ice cold 1X PBS, pelleted and resuspended in 1 ml TRI reagent solution (Ambion). RNAs were extracted using RiboPure™ Kit according to manufacturer's instructions (Ambion). RNA quantification was assessed using NanoDrop™ 1000 (Thermo Scientific) and RNA integrity by microanalysis (Agilent Bioanalyzer, Palo
Alto, CA). RNAs were diluted to 22.7 ng/µl and 250 ng were used as the input for cRNA conversion which includes amplification and biotin labelling, using the Illumina TotalPrep-96
Kit (Ambion). Purified, quality controlled (Bioanalyser and Nanodrop spectrophotometer) and normalised cRNA was hybridized to arrays according to the Illumina protocol (Illumina, WGGX DirectHyb Assay Guide 11286331 RevA). Raw image files were processed and analysed using the Beadarray package from Bioconductor. [24] on 
Reporter assays
For reporter assays, cells were transfected with 2 µg of CRE(1) reporter construct (Panomics) using Amaxa nucleofection as described above. Cells were then seeded in 12 replicates at a density of 150,000 cells per well in a 24-well plate. At each time point, cells were scraped directly in culture medium, transferred into a 96-well plate, pelleted, washed in ice cold 1X PBS and resuspended in 20 µl 1X lysis buffer (Promega). Lysates were then transferred into a dark 96-well plate and luciferase assays were performed using a Dual-Luciferase® Reporter Assay System (Promega, Madison, WI) and an automatic injection luminometer instrument (PHERAstar FS, BMG Labtech). 100 µl of Dual-Glo® Luciferase reagent was injected to each well, mixed and Firefly luciferase activity was measured 10 min later. Then, 100 µl of Dual-Glo® Stop&Glo® reagent was added to each well, mixed and Renilla luciferase activity was measured 10 min later. Activity was determined by calculating the ratio of Firefly luciferase to Renilla luciferase for each well and replicates were averaged. 
Results
SIK2 is found in plasma and is a marker for prostate cancer.
In order to identify novel biomarkers for prostate cancer in biological fluids, we conducted a study using protein arrays in order to detect the immune reactivity of plasma samples obtained from 21 patients with indolent disease and 23 with aggressive disease. [21] Autoantibody responses were able to discriminate between indolent and aggressive cases and identified salt-inducible kinase 2 (SIK2) as over-expressed in patients with aggressive disease compared to patients with indolent disease (p=2.32E-04). (Figure 1A ) The same samples were used to generate a receiver operating characteristic (ROC) curve [25] for SIK2 in plasma and confirmed that SIK2 auto-antibodies could be a good blood marker for prostate cancer. (Figure 1B) 
SIK2 knock-down and kinase-dead SIK2 reduce proliferation and viability of LNCaP cells.
In order to assess the role of SIK2 in prostate cancer, we transiently over-expressed a construct containing the wild-type sequence of the kinase (pCMV6-Entry-SIK2-myc/flag) and the corresponding construct containing the kinase-dead sequence (pCMV6-Entry-SIK2-EOS-KI-myc/flag) in LNCaP cells (Figure 2A) . The N-terminal of SIK2 contains the serine/threonine kinase domain with lysine 49 (K49) located at the putative ATP binding site that is essential for SIK2 kinase activity. The SIK2 mutant construct used had this lysine replaced with a methionine (K49M), so the activity of the kinase was abolished. [26] Cell proliferation and viability assays were then conducted using a Beckman Coulter™ Vi- To gain further insight into the mechanisms involved, we then looked at the levels of the key apoptosis regulators Bid, Bax, Bak, Caspase-3 and PARP in the LNCaP cell line knockeddown for SIK2. (Figure 3C ) SIK2 immunoblotting confirmed the efficiency of the knockdown with all three siRNAs and the equal amount of β-actin in all cell extracts confirmed that cellular integrity was unaffected. Bid levels were found to be decreased after SIK2 knockdown, which suggested it had been cleaved into its truncated form tBid, although the lower molecular weight band could not be detected (15 kDa). Bax and Bad levels were increased after knock-down with all three siRNAs, and a clear reduction in the levels of Caspase-3 and PARP accompanied by the appearance of lower molecular weight bands (17 kDa and 89 kDa respectively) were observed after knock-down with SIK2-siRNA C, which suggests that Caspase-3 and PARP were cleaved. These results indicate that SIK2 knock-down induces apoptosis in LNCaP cells via a mechanism involving the pro-apoptotic proteins Bid, Bax and Bak, and the subsequent cleavage of Caspase-3 and PARP. Again, the effects seen were the most apparent with siRNA C and least apparent with the less efficient siRNA A.
SIK2 knock-down induces a cell cycle arrest in G1 phase and delays mitotic progression of LNCaP cells.
Following on from Ahmed et al. (2010) showing that SIK2 is a centrosome kinase required for cell cycle progression from G1 to S and for the initiation of mitosis [19] , we questioned whether the effects observed on cell proliferation after SIK2 knock-down in LNCaP cells were a consequence of its implication in cell cycle regulation.
The population distribution in G1, S and G2/M phases of the cell cycle 48 h and 72 h after SIK2 knock-down in LNCaP cells was assessed using flow cytometry and DAPI staining.
There was a significant increase in the proportion of cells in G1 phase when SIK2 was knocked-down with all three siRNAs versus the non-targeting siRNA control (68.9 %, 69.9 %, 75.3 % cells in G1 for siRNAs A, B and C respectively versus 65.5 % for NT-siRNA at 48 h) ( Figure 4A and B) This indicated that SIK2 inhibition efficiently inhibited the progression of the cells through the cell cycle by arresting them in G1 phase. Consistent with this phenotype was an increase in p21 expression with all three siRNAs. (Figure 4C ) There was also a decrease in Cyclin D1 level with siRNA C and an increase in p27 was observed after knock-down with siRNA A, reflecting the cells inability to exit G1 phase after SIK2 knock-down. (Supplementary Figure 3) These data support the phenotype observed using flow cytometry, indicating that SIK2 knock-down induces a cell cycle arrest in G1 via the upregulation of p21 and p27 and the down-regulation of Cyclin D1.
A G1-cell cycle arrest can be a consequence of the inability of the cells to enter mitosis and then escaping into G1. Given that SIK2 has been shown to play a key role in the initiation of the G2/M phase transition by localising at the centrosomes in ovarian cancer cells [19] , we decided to test whether this was also the case in prostate cancer cells. γ-Tubulin is a protein member of the microtubule organising center (MTOC), which plays a role in the nucleation and polar orientation of microtubules. It localises at the centrosome and is commonly used as Figure 4B) The predominant detection of a single band using Western blotting which was enhanced after over-expression of the wild-type or kinase-dead (KI) constructs and dissipated after siRNA depletion confirmed the specificity of the antibody as previously reported. [19] (Supplementary Figure 5) The co-localisation of SIK2 with the centrosomes in prostate cancer cells strongly suggests that SIK2 might be involved in the initiation of centrosome splitting and the subsequent induction of cell entry into mitosis as it was described in ovarian cancer cells. [19] We consequently used bright field microscopy and time lapse imaging to test whether cells knocked-down for SIK2 had delayed mitotic progression. LNCaP cells were transfected with all three SIK2-siRNA sets (A, B and C) and the non-targeting siRNA (NT), and were grown Figure   3A . Interestingly, out of those 15 cells which underwent apoptosis, 2 managed to complete mitosis but entered apoptosis as soon as cytokinesis was completed (data not shown). These data strongly suggest that SIK2 is involved in the initiation of cell entry into mitosis (G2 to M) or in the progression through mitosis as it was described in ovarian cancer cells. [19] Therefore, the cell cycle arrest observed in G1 after SIK2 depletion ( Figure 4A ) is the result of cells failing to complete mitosis and escaping into G1. 
methods to test whether CREB1 activity and TORC1 phosphorylation and degradation and/or localisation were under the control of SIK2 in LNCaP cells.
Using a luciferase reporter construct containing the specific DNA binding sequences of CREB1 (cAMP response elements (CRE)) and a constitutively expressing Renilla luciferase construct, we monitored the activity of CREB1 24 h following SIK2 knock-down and 12 h following over-expression of wild-type and kinase-dead SIK2. CREB1 activity also was assessed 12 h after treatment with Forskolin, an inducer of CREB1 which raises the intracellular levels of cAMP and induces CREB1 activity through the activation of cAMPdependent protein kinase (PKA), and the subsequent phosphorylation of CREB1 at Ser133.
[28] As expected, the control Forskolin induced a dramatic increase of CREB1 activity. SIK2 depletion using three independent siRNAs or ectopic expression of kinase-dead SIK2 (KI) resulted in a significant increase in CREB1 activity. Conversely, CREB1 activity was significantly reduced when the wild-type kinase was over-expressed. (Figure 5A ) We also observed a dose-dependent increase in CREB1 activity along time when using the SIK2 inhibitor ARN3236 (Supplementary Figure 6) which confirmed the role of the kinase in CREB1 regulation.
Based on the observation of a potential regulation of CREB1 activity by SIK2, we tested whether we could validate a direct interaction between the kinase and its well-known substrate, the transducers of regulated CREB1 activity (TORC), TORC1. [14] We could demonstrate that SIK2 and TORC1 directly interact by co-immunoprecipitating both proteins in C4-2b, a prostate cancer cell line expressing high endogenous levels of the kinase. ( Figure
5B)
Protein extracts of LNCaP cells transfected with EV, WT and KI were then prepared in order to examine the effects of the kinase on the expression levels of TORC1. Western blots showed that over-expression of the wild-type kinase increased the steady-state levels of 
TORC1 but also revealed the presence of a double band when the cells were transfected with the wild-type kinase ( Figure 5C, (-CIP) ). This prompted us to explore whether this was the result of TORC1 phosphorylation by SIK2. The same extracts were therefore also treated with a phosphatase alkaline ( Figure 5C, (+CIP) ), and the disappearance of the upper band after treatment with the phosphatase confirmed the phosphorylation status of TORC1 following over-expression of the wild-type kinase. This confirmed the findings of others depicting role of SIK2 in the prevention of TORC degradation via its phosphorylation. [6-9, 11] Furthermore, we observed that the levels of phospho-CREB1 were unchanged following over-expression of the wild-type and kinase-dead SIK2, which suggests that CREB1 activity is regulated via a phosphorylation-independent mechanism. Isolated cytoplasmic and nuclear fractions for EV, WT and KI were then prepared in order to examine the effects of wild-type and kinase-dead SIK2 on the cellular distribution of TORC1.
Western blots performed on lysates obtained after cellular fractionation confirmed the presence of the transcription factor CREB1 and its phosphorylated form pCREB1 in the nucleus. They also showed a clear accumulation of TORC1 in the cytoplasmic fraction when the cells were transfected with wild-type SIK2. Conversely, lower levels of TORC1 were found in the nuclear fractions when the cells were transfected with the wild-type kinase compared to the empty vector or the kinase-dead mutant. The change in TORC1 localisation after over-expression of wild-type and kinase-dead SIK2 suggests it relates to the activity of the kinase and not merely its presence, since the kinase-dead mutant was not able to maintain TORC1 in the cytoplasm. Surprisingly, this mutant does not appear to induce more TORC1 translocation to the nucleus than the empty vector (similar levels of TORC1 were found in the nucleus with KI compared to EV) but there was a clear induction of CREB1 activity with kinase-dead SIK2 in the reporter assay. Interestingly, the cellular localisation of the wild-type and kinase-dead SIK2 was also investigated and high levels of the mutant protein were found (Supplementary Figure 5 ) Therefore, at that stage, we could not confirm their role in CREB1 regulation since their presence in the nucleus remained unproven.
SIK2 regulates a cell cycle network and a ER stress network via CREB1-dependent transcription.
After discovering a possible role for the transcription factor CREB1 and its co-activators, TORCs downstream of SIK2, we performed gene expression profiling using microarray in order to define genes and networks regulated by the SIK2. Based on the reporter assay, this approach was used in follow-up to provide an unbiased assessment of the impact on gene expression including but also extending beyond established CREB1 target genes. the wild-type SIK2 construct, the kinase-dead SIK2 construct (KI) and siRNA C (SIK2si) since this was the siRNA that gave the strongest phenotype in all the functional work performed. These conditions allowed us to identify a list of SIK2-regulated genes and pathways. We also included the condition where the cells were stimulated with Forskolin (Forsk.) in order to generate a signature of CREB1-regulated genes. The entire list of differentially expressed genes (DEG) identified in each condition are shown in Table S2 .
We first looked at the DEG in the conditions where SIK2 was knocked-down (SIK2si), kinase-dead SIK2 was over-expressed (KI) and when the cells were treated with Forskolin (Forsk.) since all three conditions induced CREB1 activity. (Figure 5A ) By comparing the gene signatures in those conditions, we aimed to identify SIK2-regulated genes dependent on CREB1 activity. A number of publications have defined CREB1 target genes based on chromatin immunoprecipitation and expression array profiling under conditions of Forskolin treatment and information is available in addition from a searchable online database, http://natural.salk.edu/CREB/. We therefore compared the genes that were differentially expressed in our cell lines with those reported to be CREB1 targets in other studies [29, 30] and selected inhibitor of DNA binding 1 (ID1), nuclear receptor subfamily 4 group A member 1 (NR4A1), homeobox A5 (HOXA5) and salt inducible kinase 1 (SIK1) for validation. Of these genes, ID1 was increased in expression by Forskolin treatment but also by knock-down of SIK2 and over-expression of the kinase-dead mutant. By contrast the other genes were either only induced by Forskolin treatment (e.g. SIK1) or indeed were inhibited in all conditions (e.g. HOXA5). This suggests that whilst CREB1 activity is enhanced by all three treatments, the impact of SIK2 knock-down or over-expression of kinase-dead SIK2 is pleiotropic and extends to other transcriptional regulators. Beyond that, the difference in Forskolin response in our study versus others, for example in respect to HOXA5 expression, suggests cell type dependency also plays a role and that systematic unraveling of the CREB1 Around half of the total number of genes down-regulated after SIK2 knock-down overlapped with the condition where the cells were treated with Forskolin (46 %) which confirmed that SIK2 regulates gene expression via CREB1, but surprisingly, only 12 % of the genes upregulated by LNCaP-SIK2-KI and 10 % of the genes down-regulated were similar to the genes differentially expressed after Forskolin treatment. This suggests that the impact of the kinase-dead mutant on gene transcription probably involves transcription factors other than CREB1. (Figure 6A ) The detailed gene lists are shown in Table S3 .
The small number of SIK2-regulated genes dependent on CREB1 activity identified in our study is not amenable to a pathway analysis but transcriptional regulation is an over- represented function when considering all eight using the DAVID gene ontology web tool.
Four fall into this functional classification (FOXO3 [31] , HOXA5 [32] , NFKBIZ [33] and CCRN4L [34] ). In addition two of the eight genes have been reported to be negative regulators of receptor tyrosine kinases (ERRFI1 and PTPRF) [35, 36] . Clearly therefore, although the number of genes is small, their impact on gene regulation and signaling is potentially significant.
In order to get a broader insight into the genes and networks downstream of SIK2, we submitted to the gene ontology data base Ingenuity® (IPA) the complete list of DEG after wild-type SIK2 and kinase-dead SIK2 over-expression and after SIK2 knock-down. The top five enriched networks associated with the categories "diseases and disorders" and "molecular and cellular functions" for each condition are shown in Supplementary Figure   8A . It is clear that networks related to cancer were considerably affected by triggering SIK2 in our prostate cancer cell line (cancer was the top disease in 4 out of 6 gene lists). This is particularly important since only one study to date has demonstrated a role for SIK2 in cancer progression. [19] The molecular and cellular functions repeatedly associated with the DEG identified in this study related to cellular growth and proliferation, cell death and survival, cell cycle and transcription. These findings agree with those of our functional study showing the involvement of SIK2 in prostate cancer cell growth, cell cycle and survival, as well as gene transcription via the regulation of the TORC/CREB1 transcriptional pathway.
We then interrogated the gene ontology data base GeneCodis [37, 38] . [29, 30] The same procedure was followed using the 152 genes up-regulated after over-expression of kinase-dead SIK2. We identified a particular enrichment for processes related to response to stress with pathways relating to ER stress, unfolded protein response (UPR) and protein The detailed lists of genes involved in the processes of "mitotic cell cycle", "protein folding"
and "response to stress" are shown in Table S4 . Owing to the profound impact of SIK2 knock-down in reducing cell proliferation and viability it was not possible to perform rescue experiments with SIK2 overexpression constructs against a knock-down background. Further dissection of these processes will therefore be pursued in future studies.
Taken together, these data suggest a hypothetical mechanism in which when SIK2 is present and catalytically active, it phosphorylates TORC1 which results in its sequestration in the cytoplasm. When in the cytoplasm, TORC1 is stabilised and not degraded as described in other studies, but its translocation into the nucleus is inhibited so CREB1-dependent gene transcription is repressed which results in cell cycle progression and ultimately, cell survival. 
Discussion
This is the first study to report that SIK2 auto-antibodies are highly expressed in patients with aggressive disease and poor prognosis and that they could be a good blood marker for the diagnosis of prostate cancer. Currently no single cohort exists with sufficient clinical followup as well as matched blood and tissue samples in which to test for SIK2 auto-antibody levels, lSIK2 tissue expression and prognosis. Biobanks are being developed that will allow this to be addressed in the longer term future and this analysis will, from a clinical perspective, be vital in determining whether SIK2 inhibitors really should be introduced in prostate cancer patients. The case for developing SIK2 inhibitors was made earlier in ovarian cancer by Ahmed et al. (2010) [19] . They showed that that SIK2 is a centrosome kinase required for the initiation of mitosis so we first considered a potential role for SIK2 in cell growth and cell cycle regulation in our cells.
In our study, we characterised the phenotypic effects of SIK2 over-expression and knockdown on prostate cancer cell lines for the first time. Our results showed that SIK2 knockdown induces a pronounced reduction in cell growth in a selection of prostate cancer cell lines (LNCaP, LNCaP-Bic, C4-2 and DuCaP) and this is accompanied by a G1 cell cycle arrest involving the cell cycle regulators p21, p27 and Cyclin D1 in LNCaP cells. We could reproduce the findings from research into ovarian cancer cells using our prostate cancer cell lines and showed that SIK2 co-localises at the centrosomes in cells in metaphase and anaphase and regulates cells entry or progression into mitosis. The most intriguing aspect of our findings was the pronounced inhibition of cell proliferation observed when the activity of the kinase was abolished (over-expression of a kinase-dead mutant of SIK2) in LNCaP cells.
This was sufficiently potent that it led to a de-selection of cells transfect with the kinase-dead mutant during our attempts to derive stable cell-lines expressing the mutant. The significance of the kinase-dead mutant on cell growth has not been reported before and indicates the importance of SIK2 downstream targets in prostate cancer progression. SIK2 mutations are detectable in TCGA (The Cancer Genome Atlas) data [39] and in the Cancer Cell-Line Encyclopedia (CCLE) [40] however none have been find in the catalytic site with the exception of a Lysine-49 to threonine mutation reported in an intestinal cell-line in the CCLE dataset. This residue is the same one that was mutated to create the kinase-dead mutant, SIK2-KI. Several studies have identified a role for SIK2 and its downstream target TORC in the regulation of cellular energy homeostasis under certain stress conditions. [5] [6] [7] [8] [9] [10] [11] It is important to take into account that SIK2 is a member of the AMPK family which are metabolic master kinases involved in the regulation of a number of metabolic processes including β-oxidation of fatty acids, lipogenesis, protein and cholesterol synthesis, as well as apoptosis. [41, 42] It was therefore crucial to consider that SIK2 is not only a centrosome kinase but it may also be implicated in the regulation of biological processes essential for the survival of prostate cancer cells. Indeed, a new function for SIK2 described in our work and previously unreported in other cancer types is its role in cell survival. We showed that SIK2 depletion induces cell death and that inhibition of its kinase activity also dramatically affects cell viability. This supports findings by Ahmed et al. (2010) , who suggested that SIK2 could present novel avenues for the development of novel cancer therapies. [19] The authors suggest that SIK2 inhibitors could be used in combination with paclitaxel, a drug of category of the taxanes, which disrupts microtubules function so inhibits the process of cell division.
Drugs which interfere with the mitotic process are commonly used for the treatment of many types of cancers. [43] For instance, docetaxel, another taxane family member, is used for the treatment of advanced prostate cancer. The cytotoxic activity of this type of drug in combination with SIK2 inhibitors might be exerted in prostate cancer compared to other cancer types since our data indicate that SIK2 not only interferes with cell cycle progression but also induces caspase-dependent apoptosis. 
We then demonstrated that SIK2 regulates the activity of the transcription factor CREB1 by interacting with its trans-activator TORC1 and altering its cellular distribution via its phosphorylation. (Figure 5B, C and D) Over-expression of a kinase-dead mutant reduced steady-state levels but also led to a loss of a band doublet which could also be removed by phosphatase treatment indicating that it represented the phosphorylated form of the protein.
( Figure 5C ) who reported that accumulation of TORC within the cytoplasm was followed by its degradation. [6] [7] [8] [9] 11 ] Interestingly, we also showed that the cellular localisation of the kinase-dead mutant was nuclear compared to the wild-type kinase.
This suggests that SIK2 regulation of CREB1-mediated transcription might be direct. Only SIK1 has been shown to act directly on CREB1 in the nucleus and all studies which report a role for SIK2 in CREB1 mediated transcription have implicated the trans-activators TORCs.
However, Horike et al. (2003) have shown that SIK2 was mostly present in the cytoplasm in mouse adipose 3T3-L1 cells, but could be translocated to the nucleus when its phosphorylatable Ser587 was replaced with Alanine (S587A). The authors suggested that SIK2 could act as a direct repressor for CREB1-mediated gene transcription, as was the case with SIK1. [26] Here, we suggest that kinase-dead SIK2 might be part of a complex with TORC which directly induces CREB1 trans-activation in the nucleus. We used a gene expression profiling approach in order to define the genes and networks regulated by the SIK2/TORC/CREB1 transcriptional pathway. We compared the genes differentially expressed in our study with two published studies in which CREB1 target genes were identified. [29, 30] Out of the genes we identified, HOXA5 was a known CREB1-regulated gene [29] which makes it an interesting candidate involved in SIK2 signaling via CREB1- 
mediated gene transcription. However, it was down-regulated in response to Forskolin treatment, SIK2 depletion and kinase-dead SIK2 over-expression which did not corroborate the enhanced CREB1 activity observed in our reporter assay. Zhang et al. (2005) further reported that certain CREB1 targets are silenced by CpG island hypermethylation, suggesting that other genomic factors can affect patterns of these genes [30] . One of the genes we selected for validation based on Rajvenskar et al.'s (2007) study, ID1 [29] , was reported to be never hypermethylated in Zhang et al.'s (2005) and was robustly induced in our experiment [30] .
We also found that about only 10 % of the genes regulated by LNCaP-SIK2-KI were similar to the genes differentially expressed after Forskolin treatment, which suggests that the impact Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. current paper. In particular, given that SIK2 and TORCs undergo nuclear-cytoplasmic translocation, it is of interest in future work to map their associated proteomes in these compartments. A recent method, rapid immuno-precipitation mass spectrometry of endogenous proteins (RIME) also provides the possibility to enrich CREB1 or indeed TORCs/SIK2 together with chromatin and begin to define the chromatin-associated protein complexes [44] . This method has revealed new co-regulators for estrogen receptor alpha and may uncover important differences in the transcription factors associating with the kinasedead or wild-type kinase [45] . These points are of fundamental importance also because of the rapid progress that is being made to develop drugs that inhibit SIK2 kinase activity, based on the previous paper in ovarian cancer, with the aim of arresting cell cycle progression. In prostate cancer, enhanced CREB1 activity has been reported to promote prostate cancer progression and cell survival. [46] In part this has been suggested to occur because CREB1 importantly also enhances the expression of a number of anti-apoptotic genes including Bcl-2 in other experimental models. [47, 48] In this setting it is also worth noting that CREB1 activity is also enhanced by other pathways and enzymes that have been associated with progression to castrate-resistant disease including CAMKII activation. [49] This is important neuronal survival and memory potentiation but the kinase also has a role in promoting cell progression in conditions of androgen deprivation. [50] Consequently in prostate cancer the possibility exists that whilst inhibiting SIK2 may inhibit cell cycle progression by the same mechanism that was reported in ovarian cancer, there may be a counteracting pressure towards survival and ultimately cancer progression through enhanced CREB1 activation.
The impact of SIK2 on cellular phenotypes, as with many kinases, can be through their kinase activity but also through protein-protein interactions. [51] By over-expressing the kinase-dead mutant we are potentially sequestering SIK2 interacting proteins in complexes that are no longer dynamically regulated by SIK2 kinase activity whereas with SIK2 knock-down, we are disrupting processes that require both SIK2-mediate kinase and SIK2-mediated protein-protein interactions. The impact of the SIK2 kinase-dead mutant on network of genes and pathways involved in cell growth and survival under certain stress conditions indicates that SIK2 protein-protein interactions are important regulators of viability. SIK2 inhibitors are under development to treat ovarian cancer based on the role of SIK2 as a regulator of mitosis. We have tested one such inhibitor with low nanomolar IC50 values in activity assays and preclinical models, ARN-3236 [22] . In reporter assays, this drug induced CREB activation in a similar manner to the kinase-dead mutant (SIK2-KI) (Supplementary Figure   6A ) underscoring the importance of considering the impact on CREB signaling in evaluating responses to these novel agents. In conclusion, our study argues for further dissection of the mechanism of action of SIK2 in prostate cancer, particularly given the metabolic features of localised disease and the cell cycle dysregulation associated with metastatic progression. (A) SIK2 autoantibodies were detected using protein arrays (ProtoPlexTM, Invitrogen) in plasma samples of two patient cohorts comprising 21 patients with indolent prostate cancer and 23 patients with aggressive prostate cancer (n = 44; n =23 in positive group and n=21 in the negative group). [20, 21] (B) The same samples were used to generate a receiver operating characteristic (ROC) curve [25] for plasma SIK2. Area under the curve (AUC) for PSA is 0.8 with a p-value of <0.0001. 
